Gilead Sciences Inc. shares rose in the extended session Tuesday after the biotech topped Wall Street estimates on earnings and revenue for the quarter. Gilead shares advanced 2.2% to $84.48. The company reported adjusted fourth-quarter earnings of $3.32 on revenue of $8.51 billion. Analysts surveyed by FactSet had forecast $3 a share on revenue of $8.16 billion. Gilead forecast full-year 2016 revenue of $30 billion to $31 billion. Analysts have forecast $31.97 billion. Separately, Gilead said its board authorized an additional $12 billion in share buybacks, and a 10% dividend increase for the second quarter.
Copyright © 2016 MarketWatch, Inc.
Continue Reading Below